# Biotech Daily Digest â€” 2025-11-15

**6 items from 1 sources**

## Summary by Source

- Endpoints News: 6 items


## Endpoints News

- **[Onshoring and data 'fidelity': What FDA wants from generic drug user fee talks](https://endpoints.news/onshoring-and-data-fidelity-what-fda-wants-from-generic-drug-user-fee-talks/)**  
  _Fri, 14 Nov 2025 20:47:05 +0000_  
  The FDA and generic drugmakers kicked off closed-door negotiations late last month over the fourth round of user fees, with the agency offering up its wish list of changes it wants to see from industry ...

- **[CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatment](https://endpoints.news/chmp-endorses-sanofi-diabetes-drug-lilly-breast-cancer-drug/)**  
  _Fri, 14 Nov 2025 19:42:51 +0000_  
  The European Medicines Agencyâ€™s human medicines committee (CHMP) recommended the approval of a Sanofi type 1 diabetes drug, Eli Lillyâ€™s oral SERD for a certain type of breast cancer, and

- **[Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipids](https://endpoints.news/zhejiang-doer-biologics-unveils-first-in-class-tri-agonist-for-high-lipids/)**  
  _Fri, 14 Nov 2025 17:56:23 +0000_  
  Meet the latest Chinese biotech with metabolic assets ready for partnering.

 Zhejiang Doer Biologics presented mid-stage data that signal that a first-of-its-kind drug is effective at cutting high lipid levels. The biotech is already in ...

- **[Bristol Myers, J&Jâ€™s next-gen blood thinner fails key trial in another setback for factor XI](https://endpoints.news/bristol-myers-jjs-next-gen-blood-thinner-fails-key-trial-in-another-setback-for-factor-xi/)**  
  _Fri, 14 Nov 2025 16:16:30 +0000_  
  Pharmaâ€™s big quest to make safer blood thinners isn't going well.

 On Friday, Bristol Myers Squibb and Johnson & Johnson announced that a Phase 3 trial of their experimental drug milvexian ...

- **[Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer program](https://endpoints.news/pfizer-reduces-stake-in-biontech-candel-pauses-pancreatic-cancer-program/)**  
  _Fri, 14 Nov 2025 16:06:15 +0000_  
  Plus, news about Century Therapeutics, nChroma Bio, Biohaven, Verastem Oncology and TandemAI:

 ðŸ§³ Pfizer trims stake in BioNTech: The US drugmaker now has around $163.5 million worth of BioNTech shares after cutting its stake ...

- **[Cartesian to pause work in form of lupus, despite trial success](https://endpoints.news/cartesian-to-pause-work-in-form-of-lupus-despite-trial-success/)**  
  _Fri, 14 Nov 2025 15:48:11 +0000_  
  Cartesian Therapeutics said it will focus development of its lead cell therapy candidate on patients with myasthenia gravis and myositis, and will pause work in another immune condition known as systemic lupus erythematosus.

 That's despite ...
